nodes	percent_of_prediction	percent_of_DWPC	metapath
Nimodipine—CYP3A4—bone cancer	0.805	1	CbGaD
Nimodipine—CACNA1S—pes—bone cancer	0.0223	0.548	CbGeAlD
Nimodipine—Phlebitis—Carboplatin—bone cancer	0.00455	0.0624	CcSEcCtD
Nimodipine—NR3C2—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00287	0.0394	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0025	0.0343	CbGpPWpGaD
Nimodipine—CACNB4—tendon—bone cancer	0.00199	0.049	CbGeAlD
Nimodipine—CACNB4—spinal cord—bone cancer	0.00192	0.0473	CbGeAlD
Nimodipine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00184	0.0253	CbGpPWpGaD
Nimodipine—CACNA1S—tendon—bone cancer	0.00171	0.042	CbGeAlD
Nimodipine—CACNB1—tendon—bone cancer	0.00159	0.0391	CbGeAlD
Nimodipine—Lactic dehydrogenase activity increased—Epirubicin—bone cancer	0.00159	0.0218	CcSEcCtD
Nimodipine—CACNB3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00157	0.0215	CbGpPWpGaD
Nimodipine—Wheezing—Cisplatin—bone cancer	0.00154	0.0211	CcSEcCtD
Nimodipine—CACNB1—spinal cord—bone cancer	0.00154	0.0377	CbGeAlD
Nimodipine—CACNB3—tendon—bone cancer	0.00153	0.0375	CbGeAlD
Nimodipine—CACNB1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00152	0.0209	CbGpPWpGaD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—RGS1—bone cancer	0.00152	0.0208	CbGpPWpGaD
Nimodipine—Fluid retention—Cisplatin—bone cancer	0.0015	0.0206	CcSEcCtD
Nimodipine—CACNB3—Regulation of insulin secretion—GNA11—bone cancer	0.00148	0.0204	CbGpPWpGaD
Nimodipine—Lactic dehydrogenase activity increased—Doxorubicin—bone cancer	0.00147	0.0202	CcSEcCtD
Nimodipine—NR3C2—Generic Transcription Pathway—ZNF77—bone cancer	0.00147	0.0201	CbGpPWpGaD
Nimodipine—Deep vein thrombosis—Methotrexate—bone cancer	0.00143	0.0196	CcSEcCtD
Nimodipine—Blood lactate dehydrogenase increased—Epirubicin—bone cancer	0.0014	0.0192	CcSEcCtD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00135	0.0185	CbGpPWpGaD
Nimodipine—Phlebitis—Cisplatin—bone cancer	0.00133	0.0183	CcSEcCtD
Nimodipine—Blood lactate dehydrogenase increased—Doxorubicin—bone cancer	0.0013	0.0178	CcSEcCtD
Nimodipine—Cardiac failure congestive—Cisplatin—bone cancer	0.00127	0.0174	CcSEcCtD
Nimodipine—Lercanidipine—CYP3A4—bone cancer	0.00127	0.14	CrCbGaD
Nimodipine—CACNA1C—connective tissue—bone cancer	0.0012	0.0296	CbGeAlD
Nimodipine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00118	0.0162	CbGpPWpGaD
Nimodipine—CACNB3—Integration of energy metabolism—GNA11—bone cancer	0.00117	0.016	CbGpPWpGaD
Nimodipine—Hyponatraemia—Cisplatin—bone cancer	0.00115	0.0158	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Cisplatin—bone cancer	0.00115	0.0158	CcSEcCtD
Nimodipine—Ileus—Epirubicin—bone cancer	0.00115	0.0158	CcSEcCtD
Nimodipine—Isradipine—CYP3A4—bone cancer	0.00115	0.126	CrCbGaD
Nimodipine—AHR—tendon—bone cancer	0.00113	0.0278	CbGeAlD
Nimodipine—CACNA1S—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00112	0.0153	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00111	0.0152	CbGpPWpGaD
Nimodipine—NR3C2—connective tissue—bone cancer	0.0011	0.0269	CbGeAlD
Nimodipine—AHR—bone marrow—bone cancer	0.0011	0.0269	CbGeAlD
Nimodipine—AHR—spinal cord—bone cancer	0.00109	0.0268	CbGeAlD
Nimodipine—Ileus—Doxorubicin—bone cancer	0.00106	0.0146	CcSEcCtD
Nimodipine—Cramp muscle—Cisplatin—bone cancer	0.00104	0.0142	CcSEcCtD
Nimodipine—CACNB2—tendon—bone cancer	0.00103	0.0252	CbGeAlD
Nimodipine—Clevidipine—CYP3A4—bone cancer	0.00101	0.111	CrCbGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000998	0.0137	CbGpPWpGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00099	0.0136	CbGpPWpGaD
Nimodipine—Sweating increased—Cisplatin—bone cancer	0.000968	0.0133	CcSEcCtD
Nimodipine—Nisoldipine—CYP3A4—bone cancer	0.000968	0.107	CrCbGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000952	0.0131	CbGpPWpGaD
Nimodipine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000927	0.0127	CbGpPWpGaD
Nimodipine—CACNB2—Regulation of insulin secretion—GNA11—bone cancer	0.000906	0.0124	CbGpPWpGaD
Nimodipine—CACNA1D—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000906	0.0124	CbGpPWpGaD
Nimodipine—Nilvadipine—CYP3A4—bone cancer	0.000905	0.0996	CrCbGaD
Nimodipine—Nitrendipine—CYP3A4—bone cancer	0.000905	0.0996	CrCbGaD
Nimodipine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00089	0.0122	CbGpPWpGaD
Nimodipine—CACNB3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000875	0.012	CbGpPWpGaD
Nimodipine—CACNA1D—Regulation of insulin secretion—GNA11—bone cancer	0.000858	0.0118	CbGpPWpGaD
Nimodipine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000857	0.0118	CbGpPWpGaD
Nimodipine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000856	0.0117	CbGpPWpGaD
Nimodipine—CACNB1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000851	0.0117	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—GNA11—bone cancer	0.000847	0.0116	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—EZH2—bone cancer	0.000844	0.0116	CbGpPWpGaD
Nimodipine—Hepatobiliary disease—Cisplatin—bone cancer	0.000838	0.0115	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000826	0.0113	CbGpPWpGaD
Nimodipine—Phosphatase alkaline increased—Epirubicin—bone cancer	0.000814	0.0112	CcSEcCtD
Nimodipine—Bradycardia—Cisplatin—bone cancer	0.00081	0.0111	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000807	0.0111	CbGpPWpGaD
Nimodipine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000806	0.0111	CbGpPWpGaD
Nimodipine—CACNA1C—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000796	0.0109	CbGpPWpGaD
Nimodipine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000793	0.0109	CbGpPWpGaD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—ATF1—bone cancer	0.000788	0.0108	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000785	0.0108	CbGpPWpGaD
Nimodipine—AHR—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000785	0.0108	CbGpPWpGaD
Nimodipine—Amlodipine—CYP3A4—bone cancer	0.000779	0.0858	CrCbGaD
Nimodipine—Fluid retention—Epirubicin—bone cancer	0.000772	0.0106	CcSEcCtD
Nimodipine—CACNA1C—Regulation of insulin secretion—GNA11—bone cancer	0.000754	0.0103	CbGpPWpGaD
Nimodipine—NR3C2—tendon—bone cancer	0.000753	0.0185	CbGeAlD
Nimodipine—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000753	0.0103	CcSEcCtD
Nimodipine—Flushing—Cisplatin—bone cancer	0.000738	0.0101	CcSEcCtD
Nimodipine—Cardiac disorder—Cisplatin—bone cancer	0.000738	0.0101	CcSEcCtD
Nimodipine—NR3C2—spinal cord—bone cancer	0.000726	0.0179	CbGeAlD
Nimodipine—Felodipine—CYP3A4—bone cancer	0.00072	0.0793	CrCbGaD
Nimodipine—Immune system disorder—Cisplatin—bone cancer	0.000719	0.00986	CcSEcCtD
Nimodipine—Fluid retention—Doxorubicin—bone cancer	0.000715	0.0098	CcSEcCtD
Nimodipine—CACNB2—Integration of energy metabolism—GNA11—bone cancer	0.000712	0.00978	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—ZNF77—bone cancer	0.000706	0.00969	CbGpPWpGaD
Nimodipine—Nifedipine—CYP3A4—bone cancer	0.000697	0.0767	CrCbGaD
Nimodipine—Nicardipine—CYP3A4—bone cancer	0.000686	0.0755	CrCbGaD
Nimodipine—Phlebitis—Epirubicin—bone cancer	0.000685	0.0094	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000679	0.00931	CcSEcCtD
Nimodipine—CACNA1D—Integration of energy metabolism—GNA11—bone cancer	0.000675	0.00926	CbGpPWpGaD
Nimodipine—Muscle spasms—Cisplatin—bone cancer	0.000666	0.00913	CcSEcCtD
Nimodipine—Cardiac failure congestive—Epirubicin—bone cancer	0.000651	0.00893	CcSEcCtD
Nimodipine—Anaemia—Cisplatin—bone cancer	0.00064	0.00878	CcSEcCtD
Nimodipine—Phlebitis—Doxorubicin—bone cancer	0.000634	0.0087	CcSEcCtD
Nimodipine—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000628	0.00862	CcSEcCtD
Nimodipine—CACNA1S—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000623	0.00855	CbGpPWpGaD
Nimodipine—CACNA1F—Alzheimers Disease—TP53—bone cancer	0.000617	0.00846	CbGpPWpGaD
Nimodipine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000611	0.00838	CbGpPWpGaD
Nimodipine—Cardiac failure congestive—Doxorubicin—bone cancer	0.000603	0.00827	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000599	0.00821	CbGpPWpGaD
Nimodipine—Hyponatraemia—Epirubicin—bone cancer	0.000593	0.00813	CcSEcCtD
Nimodipine—CACNA1C—Integration of energy metabolism—GNA11—bone cancer	0.000593	0.00813	CbGpPWpGaD
Nimodipine—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000591	0.0081	CcSEcCtD
Nimodipine—Myalgia—Cisplatin—bone cancer	0.00059	0.00809	CcSEcCtD
Nimodipine—AHR—Adipogenesis—RB1—bone cancer	0.000587	0.00805	CbGpPWpGaD
Nimodipine—Liver function test abnormal—Methotrexate—bone cancer	0.000583	0.00799	CcSEcCtD
Nimodipine—Oedema—Cisplatin—bone cancer	0.000565	0.00775	CcSEcCtD
Nimodipine—Nervous system disorder—Cisplatin—bone cancer	0.000554	0.0076	CcSEcCtD
Nimodipine—Thrombocytopenia—Cisplatin—bone cancer	0.000553	0.00759	CcSEcCtD
Nimodipine—Tachycardia—Cisplatin—bone cancer	0.000552	0.00757	CcSEcCtD
Nimodipine—Hyponatraemia—Doxorubicin—bone cancer	0.000549	0.00753	CcSEcCtD
Nimodipine—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000546	0.0075	CcSEcCtD
Nimodipine—Hyperhidrosis—Cisplatin—bone cancer	0.000546	0.0075	CcSEcCtD
Nimodipine—Liver function test abnormal—Epirubicin—bone cancer	0.000545	0.00748	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00053	0.00727	CbGpPWpGaD
Nimodipine—Hypotension—Cisplatin—bone cancer	0.000528	0.00725	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000521	0.00715	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000521	0.00714	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000515	0.00706	CcSEcCtD
Nimodipine—CACNA1D—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000506	0.00694	CbGpPWpGaD
Nimodipine—Liver function test abnormal—Doxorubicin—bone cancer	0.000504	0.00692	CcSEcCtD
Nimodipine—Dyspnoea—Cisplatin—bone cancer	0.000504	0.00691	CcSEcCtD
Nimodipine—NR3C2—Generic Transcription Pathway—NR1I2—bone cancer	0.000496	0.00681	CbGpPWpGaD
Nimodipine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000488	0.00669	CcSEcCtD
Nimodipine—Depression—Methotrexate—bone cancer	0.000485	0.00665	CcSEcCtD
Nimodipine—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000482	0.00661	CcSEcCtD
Nimodipine—AHR—Circadian rythm related genes—CDK4—bone cancer	0.000476	0.00653	CbGpPWpGaD
Nimodipine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000463	0.00635	CbGpPWpGaD
Nimodipine—Hepatobiliary disease—Methotrexate—bone cancer	0.00046	0.00631	CcSEcCtD
Nimodipine—CACNA1C—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000445	0.0061	CbGpPWpGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000444	0.00609	CbGpPWpGaD
Nimodipine—Jaundice—Epirubicin—bone cancer	0.000444	0.00609	CcSEcCtD
Nimodipine—Hepatitis—Methotrexate—bone cancer	0.000437	0.00599	CcSEcCtD
Nimodipine—Hepatobiliary disease—Epirubicin—bone cancer	0.00043	0.0059	CcSEcCtD
Nimodipine—CACNB4—Transmission across Chemical Synapses—BRAF—bone cancer	0.00043	0.0059	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—NDUFA12—bone cancer	0.000424	0.00581	CbGpPWpGaD
Nimodipine—Hypersensitivity—Cisplatin—bone cancer	0.000416	0.00571	CcSEcCtD
Nimodipine—Bradycardia—Epirubicin—bone cancer	0.000416	0.00571	CcSEcCtD
Nimodipine—Jaundice—Doxorubicin—bone cancer	0.00041	0.00563	CcSEcCtD
Nimodipine—Hepatitis—Epirubicin—bone cancer	0.000409	0.00561	CcSEcCtD
Nimodipine—Cardiac disorder—Methotrexate—bone cancer	0.000405	0.00556	CcSEcCtD
Nimodipine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000398	0.00546	CcSEcCtD
Nimodipine—Angiopathy—Methotrexate—bone cancer	0.000396	0.00543	CcSEcCtD
Nimodipine—Immune system disorder—Methotrexate—bone cancer	0.000394	0.00541	CcSEcCtD
Nimodipine—Diarrhoea—Cisplatin—bone cancer	0.000387	0.00531	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000386	0.00529	CbGpPWpGaD
Nimodipine—Bradycardia—Doxorubicin—bone cancer	0.000385	0.00528	CcSEcCtD
Nimodipine—Flushing—Epirubicin—bone cancer	0.000379	0.0052	CcSEcCtD
Nimodipine—Cardiac disorder—Epirubicin—bone cancer	0.000379	0.0052	CcSEcCtD
Nimodipine—Hepatitis—Doxorubicin—bone cancer	0.000378	0.00519	CcSEcCtD
Nimodipine—Angiopathy—Epirubicin—bone cancer	0.000371	0.00509	CcSEcCtD
Nimodipine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000369	0.00507	CbGpPWpGaD
Nimodipine—Immune system disorder—Epirubicin—bone cancer	0.000369	0.00506	CcSEcCtD
Nimodipine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000369	0.00506	CbGpPWpGaD
Nimodipine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000365	0.005	CbGpPWpGaD
Nimodipine—CACNB4—Transmission across Chemical Synapses—MDM2—bone cancer	0.00036	0.00494	CbGpPWpGaD
Nimodipine—Vomiting—Cisplatin—bone cancer	0.000359	0.00493	CcSEcCtD
Nimodipine—Rash—Cisplatin—bone cancer	0.000356	0.00489	CcSEcCtD
Nimodipine—Dermatitis—Cisplatin—bone cancer	0.000356	0.00488	CcSEcCtD
Nimodipine—Anaemia—Methotrexate—bone cancer	0.000351	0.00482	CcSEcCtD
Nimodipine—CACNB3—Metabolism—NT5C3A—bone cancer	0.000351	0.00482	CbGpPWpGaD
Nimodipine—Cardiac disorder—Doxorubicin—bone cancer	0.000351	0.00481	CcSEcCtD
Nimodipine—Flushing—Doxorubicin—bone cancer	0.000351	0.00481	CcSEcCtD
Nimodipine—NR3C2—Gene Expression—FUS—bone cancer	0.000345	0.00473	CbGpPWpGaD
Nimodipine—CACNB3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000344	0.00472	CbGpPWpGaD
Nimodipine—Angiopathy—Doxorubicin—bone cancer	0.000343	0.00471	CcSEcCtD
Nimodipine—Muscle spasms—Epirubicin—bone cancer	0.000342	0.00469	CcSEcCtD
Nimodipine—Immune system disorder—Doxorubicin—bone cancer	0.000341	0.00468	CcSEcCtD
Nimodipine—Nausea—Cisplatin—bone cancer	0.000336	0.00461	CcSEcCtD
Nimodipine—CACNB1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000334	0.00459	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—MET—bone cancer	0.00033	0.00453	CbGpPWpGaD
Nimodipine—CACNB4—Neuronal System—BRAF—bone cancer	0.000329	0.00452	CbGpPWpGaD
Nimodipine—Anaemia—Epirubicin—bone cancer	0.000329	0.00451	CcSEcCtD
Nimodipine—Myalgia—Methotrexate—bone cancer	0.000324	0.00444	CcSEcCtD
Nimodipine—Muscle spasms—Doxorubicin—bone cancer	0.000316	0.00434	CcSEcCtD
Nimodipine—Palpitations—Epirubicin—bone cancer	0.000314	0.00431	CcSEcCtD
Nimodipine—Hypertension—Epirubicin—bone cancer	0.000307	0.00421	CcSEcCtD
Nimodipine—CACNB3—Myometrial Relaxation and Contraction Pathways—JUN—bone cancer	0.000307	0.00421	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—JUN—bone cancer	0.000307	0.00421	CbGpPWpGaD
Nimodipine—Nervous system disorder—Methotrexate—bone cancer	0.000304	0.00417	CcSEcCtD
Nimodipine—Anaemia—Doxorubicin—bone cancer	0.000304	0.00417	CcSEcCtD
Nimodipine—Thrombocytopenia—Methotrexate—bone cancer	0.000304	0.00417	CcSEcCtD
Nimodipine—AHR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000303	0.00416	CbGpPWpGaD
Nimodipine—Myalgia—Epirubicin—bone cancer	0.000303	0.00415	CcSEcCtD
Nimodipine—Hyperhidrosis—Methotrexate—bone cancer	0.0003	0.00411	CcSEcCtD
Nimodipine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000299	0.00411	CbGpPWpGaD
Nimodipine—Palpitations—Doxorubicin—bone cancer	0.000291	0.00399	CcSEcCtD
Nimodipine—Oedema—Epirubicin—bone cancer	0.00029	0.00398	CcSEcCtD
Nimodipine—Hypotension—Methotrexate—bone cancer	0.00029	0.00398	CcSEcCtD
Nimodipine—CACNB3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000288	0.00395	CbGpPWpGaD
Nimodipine—Nervous system disorder—Epirubicin—bone cancer	0.000285	0.00391	CcSEcCtD
Nimodipine—Thrombocytopenia—Epirubicin—bone cancer	0.000284	0.0039	CcSEcCtD
Nimodipine—Hypertension—Doxorubicin—bone cancer	0.000284	0.0039	CcSEcCtD
Nimodipine—Tachycardia—Epirubicin—bone cancer	0.000283	0.00389	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000283	0.00388	CcSEcCtD
Nimodipine—Hyperhidrosis—Epirubicin—bone cancer	0.000281	0.00385	CcSEcCtD
Nimodipine—CACNB1—Transmission across Chemical Synapses—MDM2—bone cancer	0.00028	0.00384	CbGpPWpGaD
Nimodipine—Myalgia—Doxorubicin—bone cancer	0.00028	0.00384	CcSEcCtD
Nimodipine—Dyspnoea—Methotrexate—bone cancer	0.000277	0.00379	CcSEcCtD
Nimodipine—CACNB4—Neuronal System—MDM2—bone cancer	0.000276	0.00379	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—MMP2—bone cancer	0.000276	0.00378	CbGpPWpGaD
Nimodipine—Hypotension—Epirubicin—bone cancer	0.000271	0.00372	CcSEcCtD
Nimodipine—Oedema—Doxorubicin—bone cancer	0.000269	0.00368	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000268	0.00367	CcSEcCtD
Nimodipine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000264	0.00363	CcSEcCtD
Nimodipine—CACNB3—Axon guidance—MET—bone cancer	0.000264	0.00362	CbGpPWpGaD
Nimodipine—CACNB3—Neuronal System—BRAF—bone cancer	0.000263	0.00361	CbGpPWpGaD
Nimodipine—Nervous system disorder—Doxorubicin—bone cancer	0.000263	0.00361	CcSEcCtD
Nimodipine—Thrombocytopenia—Doxorubicin—bone cancer	0.000263	0.00361	CcSEcCtD
Nimodipine—Tachycardia—Doxorubicin—bone cancer	0.000262	0.0036	CcSEcCtD
Nimodipine—Hyperhidrosis—Doxorubicin—bone cancer	0.00026	0.00356	CcSEcCtD
Nimodipine—CACNB2—Metabolism—NDUFA12—bone cancer	0.000259	0.00355	CbGpPWpGaD
Nimodipine—Dyspnoea—Epirubicin—bone cancer	0.000259	0.00355	CcSEcCtD
Nimodipine—CACNB1—Axon guidance—MET—bone cancer	0.000257	0.00353	CbGpPWpGaD
Nimodipine—CACNB1—Neuronal System—BRAF—bone cancer	0.000256	0.00352	CbGpPWpGaD
Nimodipine—AHR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000255	0.00349	CbGpPWpGaD
Nimodipine—Hypotension—Doxorubicin—bone cancer	0.000251	0.00344	CcSEcCtD
Nimodipine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000251	0.00344	CcSEcCtD
Nimodipine—CACNA1S—Alzheimers Disease—TP53—bone cancer	0.000248	0.0034	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—NDUFA12—bone cancer	0.000245	0.00336	CbGpPWpGaD
Nimodipine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000245	0.00336	CcSEcCtD
Nimodipine—Dyspnoea—Doxorubicin—bone cancer	0.000239	0.00328	CcSEcCtD
Nimodipine—NR3C2—Gene Expression—NR1I2—bone cancer	0.000239	0.00328	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—MET—bone cancer	0.000236	0.00323	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—CDK4—bone cancer	0.000236	0.00323	CbGpPWpGaD
Nimodipine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000232	0.00318	CcSEcCtD
Nimodipine—Hypersensitivity—Methotrexate—bone cancer	0.000229	0.00314	CcSEcCtD
Nimodipine—CACNB3—Neuronal System—MDM2—bone cancer	0.000221	0.00303	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—MMP2—bone cancer	0.00022	0.00302	CbGpPWpGaD
Nimodipine—Pruritus—Methotrexate—bone cancer	0.000219	0.00301	CcSEcCtD
Nimodipine—CACNA1C—Metabolism—NDUFA12—bone cancer	0.000215	0.00296	CbGpPWpGaD
Nimodipine—CACNB1—Neuronal System—MDM2—bone cancer	0.000215	0.00295	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—NT5C3A—bone cancer	0.000215	0.00294	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—MMP2—bone cancer	0.000214	0.00294	CbGpPWpGaD
Nimodipine—Hypersensitivity—Epirubicin—bone cancer	0.000214	0.00293	CcSEcCtD
Nimodipine—Diarrhoea—Methotrexate—bone cancer	0.000212	0.00291	CcSEcCtD
Nimodipine—CACNB2—Transmission across Chemical Synapses—BRAF—bone cancer	0.00021	0.00288	CbGpPWpGaD
Nimodipine—CACNB4—Axon guidance—MMP9—bone cancer	0.000207	0.00284	CbGpPWpGaD
Nimodipine—Pruritus—Epirubicin—bone cancer	0.000205	0.00282	CcSEcCtD
Nimodipine—Dizziness—Methotrexate—bone cancer	0.000205	0.00281	CcSEcCtD
Nimodipine—CACNA1D—Metabolism—NT5C3A—bone cancer	0.000203	0.00279	CbGpPWpGaD
Nimodipine—AHR—Circadian rythm related genes—TP53—bone cancer	0.000203	0.00278	CbGpPWpGaD
Nimodipine—CACNA1D—Alzheimers Disease—TP53—bone cancer	0.000201	0.00276	CbGpPWpGaD
Nimodipine—Diarrhoea—Epirubicin—bone cancer	0.000199	0.00272	CcSEcCtD
Nimodipine—Hypersensitivity—Doxorubicin—bone cancer	0.000198	0.00271	CcSEcCtD
Nimodipine—Vomiting—Methotrexate—bone cancer	0.000197	0.00271	CcSEcCtD
Nimodipine—CACNB4—Developmental Biology—MMP2—bone cancer	0.000197	0.0027	CbGpPWpGaD
Nimodipine—Rash—Methotrexate—bone cancer	0.000196	0.00268	CcSEcCtD
Nimodipine—Dermatitis—Methotrexate—bone cancer	0.000195	0.00268	CcSEcCtD
Nimodipine—Headache—Methotrexate—bone cancer	0.000194	0.00267	CcSEcCtD
Nimodipine—Dizziness—Epirubicin—bone cancer	0.000192	0.00263	CcSEcCtD
Nimodipine—Pruritus—Doxorubicin—bone cancer	0.00019	0.00261	CcSEcCtD
Nimodipine—CACNB3—Developmental Biology—CDK4—bone cancer	0.000188	0.00259	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MET—bone cancer	0.000188	0.00259	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—MET—bone cancer	0.000188	0.00258	CbGpPWpGaD
Nimodipine—Vomiting—Epirubicin—bone cancer	0.000185	0.00253	CcSEcCtD
Nimodipine—Nausea—Methotrexate—bone cancer	0.000184	0.00253	CcSEcCtD
Nimodipine—Diarrhoea—Doxorubicin—bone cancer	0.000184	0.00252	CcSEcCtD
Nimodipine—CACNB1—Developmental Biology—CDK4—bone cancer	0.000183	0.00252	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MET—bone cancer	0.000183	0.00252	CbGpPWpGaD
Nimodipine—Rash—Epirubicin—bone cancer	0.000183	0.00251	CcSEcCtD
Nimodipine—Dermatitis—Epirubicin—bone cancer	0.000183	0.00251	CcSEcCtD
Nimodipine—Headache—Epirubicin—bone cancer	0.000182	0.00249	CcSEcCtD
Nimodipine—CACNA1C—Metabolism—NT5C3A—bone cancer	0.000179	0.00245	CbGpPWpGaD
Nimodipine—Dizziness—Doxorubicin—bone cancer	0.000178	0.00244	CcSEcCtD
Nimodipine—CACNA1C—Alzheimers Disease—TP53—bone cancer	0.000177	0.00242	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—EIF2S1—bone cancer	0.000176	0.00242	CbGpPWpGaD
Nimodipine—CACNB2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000176	0.00241	CbGpPWpGaD
Nimodipine—Nausea—Epirubicin—bone cancer	0.000172	0.00237	CcSEcCtD
Nimodipine—Vomiting—Doxorubicin—bone cancer	0.000171	0.00234	CcSEcCtD
Nimodipine—Rash—Doxorubicin—bone cancer	0.000169	0.00232	CcSEcCtD
Nimodipine—Dermatitis—Doxorubicin—bone cancer	0.000169	0.00232	CcSEcCtD
Nimodipine—Headache—Doxorubicin—bone cancer	0.000168	0.00231	CcSEcCtD
Nimodipine—CACNB4—Axon guidance—EGFR—bone cancer	0.000167	0.0023	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—MMP9—bone cancer	0.000166	0.00227	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—MET—bone cancer	0.000161	0.00221	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—MMP9—bone cancer	0.000161	0.00221	CbGpPWpGaD
Nimodipine—CACNB2—Neuronal System—BRAF—bone cancer	0.000161	0.00221	CbGpPWpGaD
Nimodipine—Nausea—Doxorubicin—bone cancer	0.00016	0.00219	CcSEcCtD
Nimodipine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000159	0.00218	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MMP2—bone cancer	0.000157	0.00216	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—MMP2—bone cancer	0.000157	0.00215	CbGpPWpGaD
Nimodipine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000157	0.00215	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—ENO2—bone cancer	0.000154	0.00211	CbGpPWpGaD
Nimodipine—NR3C2—Gene Expression—EZH2—bone cancer	0.000153	0.0021	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MMP2—bone cancer	0.000153	0.0021	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—MET—bone cancer	0.000153	0.0021	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—MMP9—bone cancer	0.000148	0.00203	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—DHFR—bone cancer	0.000143	0.00196	CbGpPWpGaD
Nimodipine—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000136	0.00187	CbGpPWpGaD
Nimodipine—CACNB2—Neuronal System—MDM2—bone cancer	0.000135	0.00185	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—MMP2—bone cancer	0.000135	0.00185	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MET—bone cancer	0.000134	0.00184	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—CDK4—bone cancer	0.000134	0.00184	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MET—bone cancer	0.000134	0.00184	CbGpPWpGaD
Nimodipine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000134	0.00184	CbGpPWpGaD
Nimodipine—CACNB3—Axon guidance—EGFR—bone cancer	0.000134	0.00184	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—GNA11—bone cancer	0.000133	0.00183	CbGpPWpGaD
Nimodipine—CACNB1—Axon guidance—EGFR—bone cancer	0.00013	0.00179	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—MMP2—bone cancer	0.000127	0.00175	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—CYP3A4—bone cancer	0.000121	0.00166	CbGpPWpGaD
Nimodipine—CACNB4—Developmental Biology—EGFR—bone cancer	0.000119	0.00164	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—MMP9—bone cancer	0.000118	0.00162	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—MMP9—bone cancer	0.000118	0.00162	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—CDK4—bone cancer	0.000115	0.00158	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MET—bone cancer	0.000115	0.00158	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—MMP9—bone cancer	0.000115	0.00158	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MMP2—bone cancer	0.000112	0.00154	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MMP2—bone cancer	0.000112	0.00154	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MET—bone cancer	0.000109	0.0015	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—CDK4—bone cancer	0.000109	0.0015	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—GSTP1—bone cancer	0.000103	0.00142	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—MMP9—bone cancer	0.000101	0.00139	CbGpPWpGaD
Nimodipine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	9.76e-05	0.00134	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MMP2—bone cancer	9.6e-05	0.00132	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—CDK4—bone cancer	9.58e-05	0.00131	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MET—bone cancer	9.58e-05	0.00131	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—MMP9—bone cancer	9.58e-05	0.00131	CbGpPWpGaD
Nimodipine—CACNB3—Developmental Biology—EGFR—bone cancer	9.55e-05	0.00131	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—NDUFA12—bone cancer	9.54e-05	0.00131	CbGpPWpGaD
Nimodipine—CACNA1S—Axon guidance—EGFR—bone cancer	9.53e-05	0.00131	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—ENO2—bone cancer	9.4e-05	0.00129	CbGpPWpGaD
Nimodipine—CACNB1—Developmental Biology—EGFR—bone cancer	9.29e-05	0.00127	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MMP2—bone cancer	9.09e-05	0.00125	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—ENO2—bone cancer	8.9e-05	0.00122	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—DHFR—bone cancer	8.72e-05	0.0012	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—MMP9—bone cancer	8.42e-05	0.00116	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—MMP9—bone cancer	8.42e-05	0.00115	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—DHFR—bone cancer	8.26e-05	0.00113	CbGpPWpGaD
Nimodipine—CACNB2—Axon guidance—EGFR—bone cancer	8.17e-05	0.00112	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—GNA11—bone cancer	8.15e-05	0.00112	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MMP2—bone cancer	7.99e-05	0.0011	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—NT5C3A—bone cancer	7.9e-05	0.00108	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—ENO2—bone cancer	7.82e-05	0.00107	CbGpPWpGaD
Nimodipine—CACNA1D—Axon guidance—EGFR—bone cancer	7.74e-05	0.00106	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—GNA11—bone cancer	7.72e-05	0.00106	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—CYP3A4—bone cancer	7.39e-05	0.00101	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—DHFR—bone cancer	7.25e-05	0.000995	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—MMP9—bone cancer	7.22e-05	0.00099	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—CYP3A4—bone cancer	6.99e-05	0.00096	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—MMP9—bone cancer	6.84e-05	0.000938	CbGpPWpGaD
Nimodipine—CACNA1S—Developmental Biology—EGFR—bone cancer	6.8e-05	0.000933	CbGpPWpGaD
Nimodipine—CACNA1C—Axon guidance—EGFR—bone cancer	6.8e-05	0.000933	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—GNA11—bone cancer	6.78e-05	0.00093	CbGpPWpGaD
Nimodipine—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.33e-05	0.000868	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—GSTP1—bone cancer	6.32e-05	0.000867	CbGpPWpGaD
Nimodipine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.24e-05	0.000856	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—CYP3A4—bone cancer	6.15e-05	0.000843	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—MMP9—bone cancer	6.01e-05	0.000824	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—GSTP1—bone cancer	5.98e-05	0.000821	CbGpPWpGaD
Nimodipine—CACNB2—Developmental Biology—EGFR—bone cancer	5.83e-05	0.0008	CbGpPWpGaD
Nimodipine—CACNA1D—Developmental Biology—EGFR—bone cancer	5.52e-05	0.000758	CbGpPWpGaD
Nimodipine—CACNB3—Metabolism—PTGS2—bone cancer	5.36e-05	0.000735	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—GSTP1—bone cancer	5.26e-05	0.000721	CbGpPWpGaD
Nimodipine—CACNA1C—Developmental Biology—EGFR—bone cancer	4.85e-05	0.000666	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—NDUFA12—bone cancer	4.43e-05	0.000608	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.67e-05	0.000504	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—ENO2—bone cancer	3.46e-05	0.000475	CbGpPWpGaD
Nimodipine—CACNB2—Metabolism—PTGS2—bone cancer	3.27e-05	0.000449	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—DHFR—bone cancer	3.21e-05	0.000441	CbGpPWpGaD
Nimodipine—CACNA1D—Metabolism—PTGS2—bone cancer	3.1e-05	0.000425	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—GNA11—bone cancer	3e-05	0.000412	CbGpPWpGaD
Nimodipine—CACNA1C—Metabolism—PTGS2—bone cancer	2.72e-05	0.000374	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—CYP3A4—bone cancer	2.72e-05	0.000373	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—GSTP1—bone cancer	2.33e-05	0.000319	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—ENO2—bone cancer	1.61e-05	0.000221	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—DHFR—bone cancer	1.49e-05	0.000205	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—GNA11—bone cancer	1.4e-05	0.000191	CbGpPWpGaD
Nimodipine—CYP3A5—Metabolism—PTGS2—bone cancer	1.21e-05	0.000165	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—GSTP1—bone cancer	1.08e-05	0.000148	CbGpPWpGaD
Nimodipine—CYP3A4—Metabolism—PTGS2—bone cancer	5.6e-06	7.69e-05	CbGpPWpGaD
